Drugs in R & D

, Volume 1, Issue 4, pp 350–351 | Cite as


Section 2: Endopeptidase Inhibitor Adis R&D Profile


Warfarin Chronic Heart Failure Captopril Amlodipine Lisinopril 


  1. 1.
    Malhotra BK, Sica DA, Khan S, et al. The effects of renal function on PK of omapatrilat. Clin Pharmacol Ther 1999; 65: 134CrossRefGoogle Scholar
  2. 2.
    Delaney CL, Jemal M, Beierle FA, et al. Steady-state PK of omapatrilat in healthy subjects. Clin Pharmacol Ther 1999; 65: 133CrossRefGoogle Scholar
  3. 3.
    Mangold B, Gielsdorf W, Norton J, et al. Omapatrilat does not affect the steady-state of warfarin. Clin Pharmacol Ther 1999; 65: 131CrossRefGoogle Scholar
  4. 4.
    Trippodo NC, Fox M, Monticello TM, et al. Simultaneous inhibition of neutral endopeptidase and angiotensin converting enzyme by omapatrilat increased survival in heart failure hamsters greater than ACE inhibition. Circulation 1998; 98 Suppl.: 781Google Scholar
  5. 5.
    McClean DR, Melton IC, Crozier IG, et al. The effects of omapatrilat, a combined inhibitor of neutral endopeptidase and angiotensin-converting enzyme, on arterial function in chronic heart failure [abstract]. Eur Heart J 1998; 19 Suppl.: 355Google Scholar
  6. 6.
    Klapholz M, Thomas I, Eng C, et al. Omapatrilat, a novel cardiovascular agent, improves hemodynamics in patients with heart failure. Circulation 1998; 98 Suppl.: 105Google Scholar
  7. 7.
    Bristol omapatrilat antihypertensive organ protection highlighted at research and development briefing for analysts. Health News Daily [online] 1997 Dec 8. Available from URL: http://www.newspage.com

Copyright information

© Adis International Limited 1999

Personalised recommendations